Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Role of Chronic Inflammation in Cardiovascular Disease (CVD) and Lung...
share announcement

Role of Chronic Inflammation in Cardiovascular Disease (CVD) and Lung Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 1885

Special Issue Editor

Dr. Kailash Gulshan

E-Mail Website
Guest Editor
Cleveland Clinic Foundation Lerner Res Inst Cleveland, OH, USA, Cleveland State University, Cleveland, OH, USA
Interests: Nlrp3 inflammasome and IL-1β pathway in cardiovasciular disease and lung cancer

Special Issue Information

Dear Colleagues,

Based on the American Heart Association’s 2016 Heart Disease and Stroke Statistics update; by the year 2030 approximately 40 % of US population is projected to have some form of cardiovascular disease (CVD). The recently concluded Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial showed that anti-IL-1β therapy can reduce CVD, independent of lipid levels. One of the interesting findings from the CANTOS trial was a retrospective analysis showing a marked reduction in the hazard ratio (HR) of lung cancer incidence in the two treatment groups (150 and 300 mg) compared with placebo controls, with a HR of 0.33 after 3.7 years of follow-up. Based on SEER cancer statistics, lung cancer accounts for 13% of all new cancer diagnoses but 24% of all cancer deaths, making it the leading cause of cancer deaths.

The delicate balance between atheroprotective pathways vs. atherogenic pathways can decide the fate of atherosclerotic plaque progression/regression. A similar scenario is observed in lung cancer where inflammation and immunosuppression confer antagonizing effects in the tumor microenvironment to modulate the interaction between immune and cancerous cells.

Given that both CVD and the lung cancer field involve multiple common pathways and are promoted by presence of chronic inflammation in humans, the idea of combining lipid-lowering therapeutics and anticancer therapy with anti-inflammatory drugs is now looking more attractive than ever. Thus, identification of the novel players involved in inflammation-mediated progression of CVD and lung cancer is of high importance. Drugs targeting these pathways can serve as stand-alone therapy or may serve as adjuvant therapy along with statin or anticancer drugs.

We invite innovative and thorough studies regarding role of chronic inflammation in CVD and lung cancer to be a part of this timely and highly impactful Special Issue in the Journal of Clinical Medicine.

Dr. Kailash Gulshan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Inflammation
  • Cholesterol
  • Nlrp3 inflammasome
  • IL-1b
  • Pyroptosis
  • Gasdermin
  • Caspases
  • TLRs
  • NETosis

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 253 KiB  
Article
The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patients—The CARDAS Study
by Milad Baniaamam, Sjoerd C. Heslinga, Laura Boekel, Thelma C. Konings, M. Louis Handoko, Otto Kamp, Vokko P. van Halm, Irene E. van der Horst-Bruinsma and Mike T. Nurmohamed
J. Clin. Med. 2021, 10(21), 5069; https://doi.org/10.3390/jcm10215069 - 29 Oct 2021
Cited by 10 | Viewed by 1542
Abstract
Objectives: The aim of the present study was to determine the prevalence of specific cardiac manifestations, i.e., conduction disorders, valvular disease and diastolic left ventricular (LV) dysfunction, in a large cross-sectional controlled cohort of elderly ankylosing spondylitis (AS) patients. Methods: This cross-sectional study [...] Read more.
Objectives: The aim of the present study was to determine the prevalence of specific cardiac manifestations, i.e., conduction disorders, valvular disease and diastolic left ventricular (LV) dysfunction, in a large cross-sectional controlled cohort of elderly ankylosing spondylitis (AS) patients. Methods: This cross-sectional study assessed the prevalence of valvular disease, conduction disorders and LV dysfunction in 193 randomly selected AS patients compared with 74 osteoarthritis (OA) controls aged 50–75 years. Patients underwent conventional and tissue Doppler echocardiography in combination with clinical and laboratory assessments. Multivariate regression analyses were performed to compare the odds of mitral valve regurgitation (MVR) and aortic valve regurgitation (AVR) between AS patients and OA controls. Results: The prevalence of diastolic dysfunction was trivial and comparable in AS patients compared to controls (respectively, 4% and 3%) and had no further clinical relevance. In addition, the prevalence of conduction disturbances was similar in both groups, with little clinical relevance, respectively 23% vs. 24%. The prevalence of AVR was significantly higher in AS patients compared to the controls, respectively 23% (9% trace, 12% mild, 1% moderate, 1% severe, 1% prosthesis) vs. 11%, p = 0.04. After correcting for age, sex and CV risk factors, AS patients had an odds ratio of 4.5 (95% CI 1.1–13.6) for AVR compared to the controls. In contrast, the prevalence values of MVR were similar and mostly not clinically relevant in AS patients and controls, respectively 36% and 32% and p = 0.46. Conclusion: The prevalence of diastolic LV dysfunction and conduction disorders was mostly not clinically relevant, and similar in AS patients and controls. However, AS patients had an up to five times increased odds to develop AVR compared to controls. Therefore, echocardiographic screening of elderly (50–75 years) AS patients should be considered. Full article
(This article belongs to the Special Issue Role of Chronic Inflammation in Cardiovascular Disease (CVD) and Lung Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop